Phase 3 Trial of Segmentectomy Surgery for Solid-Dominant Invasive Lung Adenocarcinoma Tumors Sized 2 to 3 cm

What this Trial Is About

Researchers are evaluating the therapeutic effect of segmentectomy for patients with solid-dominant invasive lung adenocarcinoma measuring 2 to 3 centimeters. The study focuses on understanding the 5-year disease-free survival rate in these patients and assessing lung function after surgery. This is a Phase III clinical trial sponsored by Fudan University that aims to confirm the benefits of segmentectomy as a surgical treatment option. Participants will undergo segmentectomy, a surgical procedure that removes part of a lung lobe containing the tumor while preserving more healthy lung tissue. The surgery is performed on patients with solid-dominant invasive lung cancer tumors sized between 2 and 3 centimeters, with specific criteria regarding tumor characteristics such as consolidation-to-tumor ratio. The trial is a single-arm, multi-center study where all participants receive this procedure. During the study, participants will be monitored for outcomes such as 5-year disease-free survival and overall survival, lung function tests at 6 months and one year after surgery, tumor recurrence and metastasis, surgical completion rates, and surgery-related complications. Follow-up assessments will include lung function tests and ongoing evaluations up to 5 years to track patient health and cancer status. The total participation period involves both immediate post-surgery assessments and long-term follow-up to gather comprehensive data on treatment impact.

Segmentectomy for Solid-dominant Lung Cancer